Pierangeli A, Statzu M, Nenna R, Santinelli L, Petrarca L, Frassanito A, et al. Interferon lambda receptor 1 (IFNL1R) transcript is highly expressed in rhinovirus bronchiolitis and correlates with disease severity. J Clin Virol. 2018;102:101-109 pubmed publisher

Corry J, Arora N, Good C, Sadovsky Y, Coyne C. Organotypic models of type III interferon-mediated protection from Zika virus infections at the maternal-fetal interface. Proc Natl Acad Sci U S A. 2017;114:9433-9438 pubmed publisher

Sung P, Hong S, Chung J, Kim S, Park S, Kim H, et al. IFN-λ4 potently blocks IFN-α signalling by ISG15 and USP18 in hepatitis C virus infection. Sci Rep. 2017;7:3821 pubmed publisher

Jarret A, McFarland A, Horner S, Kell A, Schwerk J, Hong M, et al. Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. Nat Med. 2016;22:1475-1481 pubmed publisher

Persson B, Jaffe A, Fearns R, Danahay H. Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation. PLoS ONE. 2014;9:e102368 pubmed publisher

Ding S, Khoury Hanold W, Iwasaki A, Robek M. Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth. PLoS Biol. 2014;12:e1001758 pubmed publisher

Wilson T, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487:505-9 pubmed publisher

Lee S, Lim J, Choi Y, Kim W, Moon S. Interleukin-28A triggers wound healing migration of bladder cancer cells via NF-?B-mediated MMP-9 expression inducing the MAPK pathway. Cell Signal. 2012;24:1734-42 pubmed publisher

Li Q, Kawamura K, Okamoto S, Fujie H, Numasaki M, Namba M, et al. Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-? genes produced anti-tumour effects. Br J Cancer. 2011;105:1302-12 pubmed publisher

Prescott J, Hall P, Acuna Retamar M, Ye C, Wathelet M, Ebihara H, et al. New World hantaviruses activate IFNlambda production in type I IFN-deficient vero E6 cells. PLoS ONE. 2010;5:e11159 pubmed publisher

Witte K, Gruetz G, Volk H, Looman A, Asadullah K, Sterry W, et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 2009;10:702-14 pubmed publisher

Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, et al. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer. 2009;125:367-73 pubmed publisher

Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine. 2005;31:109-18 pubmed